Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sánchez-Sorzano CO, Esteban M.
Here we describe the design and strength of a new synthetic Late-Early Optimized (LEO) vaccinia virus (VACV) promoter used as transcriptional regulator of GFP expression during MVA infection.
In contrast to the described synthetic VACV promoter (pS), LEO induces in vitro significantly higher levels of GFP expression within the first hour after infection, which correlates with an enhancement in the GFP-specific CD8 T cell response detected in vivo demonstrating its potential use in future vaccines.